TMP1: Thymidylate synthase
Protein in Candida albicans that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on TMP1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| FlucytosineBoxed warning | Approved | Bausch Health | Small molecule | InhibitorThymidylate synthase inhibitor | 4 |
| Platform Trial For Cryptococcal Meningitis (PLATFORM-CM) | Flucytosine | Phase 2 / Phase 3 | Recruiting | David Boulware | Oct 30, 2024 |
| Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) | Flucytosine | Phase 3 | Not yet recruiting | Duke University | Jul 29, 2024 |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Flucytosine | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | Jul 16, 2024 |
| DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | Flucytosine | Phase 2 | Recruiting | Ashish Shah | Feb 20, 2024 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364680, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets